CompletedPhase 3

L-Arginine in Children Having Sickle Cell Disease With Increased Tricuspid Regurgitant Jet Velocity

Egypt50 participantsStarted 2022-07-25

Plain-language summary

This study aims to investigate the possible efficacy and safety of L-Arginine in children having Sickle Cell Disease with increased Tricuspid Regurgitant Jet Velocity

Who can participate

Age range5 Years – 18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * children having Sickle Cell Disease with increased Tricuspid Regurgitant Jet Velocity * age 5-18 years Exclusion Criteria: * Another chronic hemolytic anemia. * Patients with documented causes of pulmonary hypertension other than SCD. * Allergy to L-arginine. * Patients with Asthma. * Hepatic dysfunction: serum Alanine Aminotransferase (ALT) \> 3X upper value. * Renal dysfunction: Creatinine level greater than or equal to 1.2 mg/dl.

What they're measuring

change in tricuspid regurgitant jet velocity (TRJV) detected by Color Doppler Echocardiography

Timeframe: 3 months

Trial details

NCT IDNCT05470998

SponsorTanta University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-10-01

View on ClinicalTrials.gov More Sickle Cell Disease trials